Congestive Heart Failure by
the Numbers1

More than 8 million Americans are estimated to have CHF by 2030, resulting in

$53Billion*

in direct CHF medical costs

$70Billion

indirect CHF costs

$160Billion*

total cardiovascular care direct costs 

$3,594

Per patient

incremental adjusted annual medical costs for CHF

$32,955

Per patient

total annual medical costs for CHF

Approximately

6.7M Americans

over the age of 20 have heart failure and the revalence is expected to rise to

8.5M by 2030

*2010 dollars
1. J Card Fail. 2023; 29 P1412-1451

Technology Overview: Nasal Diuretic

Loop diuretics are one of the top medications used to manage fluid overload caused by congestive heart failure (CHF), liver, and kidney disease.

Medications delivered nasally avoid the absorption-limiting effects of first-pass metabolism and are transported via the nasal capillary network to systemic circulation.

Our nasal diuretic provides a self-administered outpatient option for patients suffering from congestion.

rsq-mobile-graphic

Corstasis Therapeutics’ products, including RSQ-777 and related investigational therapies, are under clinical investigation and have not been approved by regulatory authorities, including the U.S. Food and Drug Administration (FDA) or equivalent global agencies. Their safety, efficacy, and clinical use have not been established. All information provided is intended for educational and informational purposes only and should not be construed as medical advice or a recommendation for use. For questions about medical conditions or treatment options, please consult a qualified healthcare professional.